About
Kalaris Therapeutics is a clinical-stage biopharmaceutical company developing an engineered dual-targeting biologic, TH103, aimed at improving anti-VEGF treatment durability and outcomes for retinal diseases including neovascular age-related macular degeneration.
Explore Kalaris Therapeutics's full profile on Brouky
Funding rounds, investor list, and risk signals — unlock with a subscription.